{"analyses":[{"ciLowerLimit":"0.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.81","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.57","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.4","upperLimit":"42.9","value":"42.9"},{"comment":"Follow-up is not long enough to estimate an upper bound for median progression-free survival","groupId":"OG001","lowerLimit":"11.5","upperLimit":"NA","value":"24.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"Time from date of randomization to the first documentation of disease progression by independent review or to death due to any cause, whichever comes first","dispersionType":"95% Confidence Interval","groups":[{"description":"brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"},{"description":"placebo every 3 weeks by IV infusion","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intention-to-Treat analysis set","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years","title":"Progression-free Survival by Independent Review","type":"PRIMARY","unitOfMeasure":"months"}